CLAIM CARD
The current evidence base presents a notable tension: while mechanistic plausibility supports rapamycin's potential immunomodulatory benefits, the available clinical data remain limited to protocol descriptions without outcome validation. The RIVASTIM trial (Tunbridge 2022) exemplifies the gap between preclinical promise and clinical evidence generation. This tension is not unique to immune outcomes but reflects a broader pattern across the rapamycin literature, where mechanistic insights from preclinical models await confirmation in human trials. The context-dependent nature of rapamycin's immune effects—potentially enhancing responses in some populations while suppressing them in others—complicates straightforward synthesis of the available evidence.
Evidence grade: exploratory
Contradiction status: none
Publication: 1ece772b-d3e4-4ad0-b090-ac7e9ea4a1d6
Provenance: Derivation Web chain
Citation Support
source_1Mandrioli 2023source_2Lin 2022source_3Moel 2025source_4Gkioni 2025source_5Zhou 2024